<DOC>
	<DOCNO>NCT02188771</DOCNO>
	<brief_summary>This Phase I , prospective , active-controlled , randomize , open-label , clinical trial design assess safety tolerability single intra-articular injection RegenoGel-SP treatment OA . RegenoGel-SP compose fibrinogen plasma link high molecular weight HA . The viscoelastic property result combination two natural macromolecule enhance joint surface associate factor generate viscoelastic gel superior stability mechanical integrity .</brief_summary>
	<brief_title>A Phase I , Prospective , Randomized , Open-label , Active-Controlled Clinical Trial Safety Evaluation Intra-articular Injection RegenoGel-SP Treatment Moderate Severe Osteoarthritis</brief_title>
	<detailed_description>Eighteen subject randomize sequentially assign RegenoGel-SP hyaluronic acid ( HA ) treatments 2:1 basis , respectively . Treatment group assign per randomization list prepare prior start study . Randomization do Enrollment ( Visit 2 ) . Neither surgeon subject blind treatment . Subjects monitor 6 month follow treatment . Following signing Informed Consent form ( Visit 1 ) , subject conform inclusion criterion answer questionnaire grade symptom , pain level overall functional performance . Subjects evaluate vital sign , blood hematology , chemistry , INR , aPTT ECG , subject 30-40ml blood withdrawal use production autologous RegenoGel-SP . Subjects randomize receive RegenoGel-SP receive single , intra-articular injection ( Visit 2 ) , subject randomize receive HA treatment ( Euflexxa® ) inject 3 intra-articular weekly injection ( Visits 2-4 ) . Subjects treat RegenoGel-SP attend visit 3 4 receive treatment . All subject return Observation visit 6 week , 3 month 6 month follow treatment ( Visits 5-7 ) . During treatment observation visit , subject monitor safety parameter ( local systemic AEs , blood work analysis ) response treatment use questionnaire .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Subject sign date informed consent form Subject experience pain intend study knee VAS score ≥ 5 Subject degenerative change intend study knee categorize grade IIIIV Kellgren Lawrence base upon stand posterioranterior lateral radiograph knee candidate TKR Subject Body Mass Index ( BMI ) 18.5 35 Subject fail conservative treatment intend study knee , include measure weight reduction , physical therapy , hydrotherapy , analgesic , nonsteroidal antiinflammatory drug ( NSAIDs ) and/or intraarticular injection Subjects history significant knee trauma intend study knee previous arthroscopic surgery intend study knee within last 3 month precede screen Subject intraarticular injection intend study knee within 6 month prior Screening Subject unable stop chronic administration pain medication ( include paracetamol ) , day study visit completion study visit . Subject history Psoriatic Arthritis , Rheumatoid Arthritis , inflammatory condition associate arthritis Subject superficial wound area intend study knee Subject know sensitivity treatment component , egg , rubber latex Subject history anaphylactic shock severe systemic response adverse event human blood product Subject clinically significant abnormal finding ( e.g. , laboratory result ECG ) screen Subject clinically significant abnormal INR aPTT coagulation result . Subject hemoglobin concentration 10.5 Subject positive Human Immunodeficiency Virus / Aquired Immunodeficiency Syndrome ( HIV/AIDS ) , Hepatitis B C viral infection , acute chronic liver disease Subject ever cellulitis low extremity , superficial deep vein thrombosis , family history clot disorder Subject cancer past 5 year surgery involve chest , abdomen , pelvis , low extremity past year Subject receive investigational device product within 30 day Visit l Subject recent ( acute ) chronic medical , psychiatric , social problem might : 1 ) interfere Subject 's performance completion trial ; 2 ) obfuscate Subject 's study data ; 3 ) render Subject unable understand nature , scope , possible consequence study Subject receive oral inject anticoagulant Subject ever abuse drug alcohol ( selfreported ) Subject receive blood transfusion within 6 month prior Visit 1 . Subject donate blood blood product within 3 month prior Visit 1 . Subject elective surgery kind low extremity elective surgery require general anesthesia schedule course trial</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Moderate Severe OA</keyword>
	<keyword>VAS score ≥ 5</keyword>
	<keyword>grade III-IV Kellgren Lawrence OA</keyword>
	<keyword>subject fail conservative treatment</keyword>
	<keyword>subject candidate total knee replacement ( TKR )</keyword>
	<keyword>subject 45 75 year old</keyword>
	<keyword>subject experience pain intend study knee VAS score ≥ 5</keyword>
	<keyword>subject Body Mass Index ( BMI ) 18.5 35</keyword>
</DOC>